|
Vaccine Detail
Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP |
Vaccine Information |
- Vaccine Name: Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004450
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- HSP47
gene engineering:
- Type: DNA vaccine construction
- Description: Vector pcDNA3.1(+) expressed heat shock proteins (Zhang et al., 2007).
- Detailed Gene Information: Click Here.
- Prostate stem cell antigen
gene engineering:
- Type: DNA vaccine construction
- Description: Vector pcDNA3.1(+) expressed prostate stem cell antigen (PSCA) (Zhang et al., 2007).
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000158
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: The growth of RM-PSCA tumors was significantly slower in the groups vaccinated with PSCA-HSP, HSP-PSCA, and PSCA + HSP plasmids compared with that in the groups treated with PBS or pcDNA-HSP (P < 0.05). Furthermore, the survival time of mice vaccinated with PSCA-HSP (range 40–69 days) was significantly longer as compared with that of groups injected with HSP-PSCA and PSCA + HSP plasmids (P = 0.016 and P = 0.015, respectively) (Zhang et al., 2007).
|
References |
Zhang et al., 2007: Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. The journal of gene medicine. 2007; 9(8); 715-726. [PubMed: 17595048].
|
|